36 related articles for article (PubMed ID: 33521925)
1. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox.
Amano S; Kaino S; Shinoda S; Harima H; Matsumoto T; Fujisawa K; Takami T; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2020 Jul; 20(1):681. PubMed ID: 32698792
[TBL] [Abstract][Full Text] [Related]
2. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.
Messa E; Carturan S; Maffè C; Pautasso M; Bracco E; Roetto A; Messa F; Arruga F; Defilippi I; Rosso V; Zanone C; Rotolo A; Greco E; Pellegrino RM; Alberti D; Saglio G; Cilloni D
Haematologica; 2010 Aug; 95(8):1308-16. PubMed ID: 20534700
[TBL] [Abstract][Full Text] [Related]
3. Potential anticancer effect of free and nanoformulated Deferasirox for breast cancer treatment:
Abdel-Wahab ND; Kabil MF; El-Sherbiny IM; Salama MF; El-Sayed G; El-Sherbini ES
Drug Dev Ind Pharm; 2024 Mar; 50(3):223-235. PubMed ID: 38305197
[TBL] [Abstract][Full Text] [Related]
4. Takes one to B1a: Dismantling the origin of mantle cell lymphoma.
Beaudin AE
J Exp Med; 2021 Oct; 218(10):. PubMed ID: 34529750
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Study of Multifunctional Cyclodextrin-Deferasirox Hybrids.
Gascon JM; Oliveri V; McGown A; Kaya E; Chen YL; Austin C; Walker M; Platt FM; Vecchio G; Spencer J
ChemMedChem; 2019 Aug; 14(16):1484-1492. PubMed ID: 31162826
[TBL] [Abstract][Full Text] [Related]
6. Deferasirox Causes Leukaemia Cell Death through Nrf2-Induced Ferroptosis.
Hsu WY; Wang LT; Lin PC; Liao YM; Hsu SH; Chiou SS
Antioxidants (Basel); 2024 Mar; 13(4):. PubMed ID: 38671872
[TBL] [Abstract][Full Text] [Related]
7. Metformin Inhibits Abdominal Aortic Aneurysm Formation through the Activation of the AMPK/mTOR Signaling Pathway.
He J; Li N; Fan Y; Zhao X; Liu C; Hu X
J Vasc Res; 2021; 58(3):148-158. PubMed ID: 33601368
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
Morschhauser F; Feugier P; Flinn IW; Gasiorowski R; Greil R; Illés Á; Johnson NA; Larouche JF; Lugtenburg PJ; Patti C; Salles GA; Trněný M; de Vos S; Mir F; Samineni D; Kim SY; Jiang Y; Punnoose E; Sinha A; Clark E; Spielewoy N; Humphrey K; Bazeos A; Zelenetz AD
Blood; 2021 Feb; 137(5):600-609. PubMed ID: 33538797
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma.
Strati P; Ahmed S; Furqan F; Fayad LE; Lee HJ; Iyer SP; Nair R; Nastoupil LJ; Parmar S; Rodriguez MA; Samaniego F; Steiner RE; Wang M; Pinnix CC; Horowitz SB; Feng L; Sun R; Claussen CM; Hawkins MC; Johnson NA; Singh P; Mistry H; Johncy S; Adkins S; Kebriaei P; Shpall EJ; Green MR; Flowers CR; Westin J; Neelapu SS
Blood; 2021 Jun; 137(23):3272-3276. PubMed ID: 33534891
[TBL] [Abstract][Full Text] [Related]
10. Expression of the novel tumour suppressor sterile alpha motif and HD domain-containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma.
Xagoraris I; Vassilakopoulos TP; Drakos E; Angelopoulou MK; Panitsas F; Herold N; Medeiros LJ; Giakoumis X; Pangalis GA; Rassidakis GZ
Br J Haematol; 2021 May; 193(3):488-496. PubMed ID: 33528031
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of water fraction from Dioscorea cirrhosa on oxidative stress and apoptosis in H9c2 cardiomyocytes induced by H2O2.
Liu C; Lu D; You J; Lu Y; Sun J; Pan J; Wang Y; Wang A; Lan Y; Li Y; Liu T
J Tradit Chin Med; 2021 Feb; 41(1):51-58. PubMed ID: 33522197
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma.
Yu T; Xu-Monette ZY; Yu L; Li Y; Young KH
Cell Death Dis; 2023 Nov; 14(11):771. PubMed ID: 38007476
[TBL] [Abstract][Full Text] [Related]
13. Identifying and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing.
Jeon Y
Korean J Intern Med; 2023 Nov; 38(6):785-786. PubMed ID: 37939662
[No Abstract] [Full Text] [Related]
14. CHIR99021 Maintenance of the Cell Stemness by Regulating Cellular Iron Metabolism.
Han Y; He Y; Jin X; Xie J; Yu P; Gao G; Chang S; Zhang J; Chang YZ
Antioxidants (Basel); 2023 Feb; 12(2):. PubMed ID: 36829936
[TBL] [Abstract][Full Text] [Related]
15. Repurposed Drugs in Gastric Cancer.
Araújo D; Ribeiro E; Amorim I; Vale N
Molecules; 2022 Dec; 28(1):. PubMed ID: 36615513
[TBL] [Abstract][Full Text] [Related]
16. Degradation strategy of cyclin D1 in cancer cells and the potential clinical application.
Chen S; Li L
Front Oncol; 2022; 12():949688. PubMed ID: 36059670
[TBL] [Abstract][Full Text] [Related]
17. Deferasirox induces cyclin D1 degradation and apoptosis in mantle cell lymphoma in a reactive oxygen species- and GSK3β-dependent mechanism.
Samara A; Shapira S; Lubin I; Shpilberg O; Avigad S; Granot G; Raanani P
Br J Haematol; 2021 Feb; 192(4):747-760. PubMed ID: 33521925
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.
Vazana-Barad L; Granot G; Mor-Tzuntz R; Levi I; Dreyling M; Nathan I; Shpilberg O
Leuk Lymphoma; 2013 Apr; 54(4):851-9. PubMed ID: 23020673
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.
Lo RK; Kwong YL
Ann Hematol; 2014 Feb; 93(2):255-65. PubMed ID: 23949314
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
